Utility of a New Bolus-injectable Nanoparticle for Clinical Cancer Staging
Open Access
- 1 December 2007
- Vol. 9 (12) , 1160-1165
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Treatment options in lymph node‐positive prostate cancerCancer, 2006
- The safety and efficacy of ferumoxytol therapy in anemic chronic kidney disease patientsKidney International, 2005
- Pharmacokinetic Study of Ferumoxytol: A New Iron Replacement Therapy in Normal Subjects and Hemodialysis PatientsAmerican Journal of Nephrology, 2005
- Sensitive, Noninvasive Detection of Lymph Node MetastasesPLOS Medicine, 2004
- First‐pass contrast‐enhanced magnetic resonance angiography in humans using ferumoxytol, a novel ultrasmall superparamagnetic iron oxide (USPIO)‐based blood pool agentJournal of Magnetic Resonance Imaging, 2004
- Superparamagnetic Iron Oxide NanoparticlesTopics in Magnetic Resonance Imaging, 2004
- Noninvasive Detection of Clinically Occult Lymph-Node Metastases in Prostate CancerNew England Journal of Medicine, 2003
- Researchers discuss NIH's nanotechnology initiativeNature Biotechnology, 2000
- MR imaging of pelvic lymph nodes in primary pelvic carcinoma with ultrasmall superparamagnetic iron oxide (combidex): Preliminary observationsJournal of Magnetic Resonance Imaging, 1997
- Monocrystalline iron oxide nanocompounds (MION): Physicochemical propertiesMagnetic Resonance in Medicine, 1993